8-K
filed June 9, 2023, 7:59 PM ET
ticker OVID
CIK 0001636651
other
confidence high
sentiment neutral
materiality 0.10
Ovid Therapeutics shareholders elect directors, approve say-on-pay, ratify auditor
Ovid Therapeutics Inc.
- Karen Bernstein re-elected with 39.7M for, 5.1M withheld; Jeremy Levin re-elected with 44.5M for, 0.4M withheld (16.5M broker non-votes).
- Say-on-pay approved: 44.7M for, 113,666 against, 40,903 abstain (16.5M broker non-votes).
- Shareholders recommended one-year frequency for say-on-pay (44.0M for one year, 793,928 for three years).
- Ratification of KPMG as auditor for FY2023: 61.2M for, 65,728 against, 2,922 abstain.
- Board determined future say-on-pay votes will be annual until at least 2029.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Ovid Therapeutics Inc. shareholders approved Advisory vote on the frequency of future advisory votes on executive compensation at the 2023-06-08 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2023-06-08
Exact text from the filing
Proposal 3 : The Company’s stockholders recommended, on an advisory basis, a frequency of “one year” for the advisory vote to approve the compensation paid to the Company’s named executive officers by the votes set forth in the table below: One Year Two Year Three Year Abstain Broker Non-Votes 44,015,622 11,727 793,928 14,642 16,459,080
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Ovid Therapeutics Inc. shareholders approved Ratification of the selection of KPMG LLP as the independent registered public accounting firm at the 2023-06-08 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-08
Exact text from the filing
Proposal 4 : The Company’s stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023 by the votes set forth in the table below: For Against Abstain 61,226,349 65,728 2,922
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Ovid Therapeutics Inc. shareholders approved Advisory vote to approve the compensation paid to the Company's named executive officers at the 2023-06-08 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-08
Exact text from the filing
Proposal 2 : The Company’s stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers, as disclosed in the Proxy Statement, by the votes set forth in the table below: For Against Abstain Broker Non-Votes 44,681,350 113,666 40,903 16,459,080
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Ovid Therapeutics Inc. shareholders approved Election of Directors at the 2023-06-08 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-08
Exact text from the filing
Proposal 1 : The Company’s stockholders elected all of the nominees for director to serve a three-year term until the Company’s 2026 annual meeting of stockholders, or until their respective successors are duly elected and qualified, by the votes set forth in the table below: Nominee For Withheld Broker Non-Votes Karen Bernstein 39,704,019 5,131,900 16,459,080 Jeremy M. Levin 44,455,812 380,107 16,459,080
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.